Created at Source Raw Value Validated value
June 25, 2024, noon usa

1. previous exposure to covid-19 convalescent plasma. 2. adverse reaction to plasma proteins in medical history. 3. interval \>72h since endotracheal intubation. 4. current or imminent necessity of ecmo treatment. 5. pre-existing copd gold stage 4. 6. chronic congestive heart failure nyha ≥3. 7. pre-existing left ventricular ejection fraction \<30%.

1. previous exposure to covid-19 convalescent plasma. 2. adverse reaction to plasma proteins in medical history. 3. interval \>72h since endotracheal intubation. 4. current or imminent necessity of ecmo treatment. 5. pre-existing copd gold stage 4. 6. chronic congestive heart failure nyha ≥3. 7. pre-existing left ventricular ejection fraction \<30%.

Nov. 16, 2021, 6:30 p.m. usa

previous exposure to covid-19 convalescent plasma. adverse reaction to plasma proteins in medical history. interval >72h since endotracheal intubation. current or imminent necessity of ecmo treatment. pre-existing copd gold stage 4. chronic congestive heart failure nyha ≥3. pre-existing left ventricular ejection fraction <30%.

previous exposure to covid-19 convalescent plasma. adverse reaction to plasma proteins in medical history. interval >72h since endotracheal intubation. current or imminent necessity of ecmo treatment. pre-existing copd gold stage 4. chronic congestive heart failure nyha ≥3. pre-existing left ventricular ejection fraction <30%.

Jan. 17, 2021, 12:31 a.m. usa

1. previous exposure to covid-19 convalescent plasma. 2. adverse reaction to plasma proteins in medical history. 3. interval >72h since endotracheal intubation. 4. current or imminent necessity of ecmo treatment. 5. pre-existing copd gold stage 4. 6. chronic congestive heart failure nyha ≥3. 7. pre-existing left ventricular ejection fraction <30%.

1. previous exposure to covid-19 convalescent plasma. 2. adverse reaction to plasma proteins in medical history. 3. interval >72h since endotracheal intubation. 4. current or imminent necessity of ecmo treatment. 5. pre-existing copd gold stage 4. 6. chronic congestive heart failure nyha ≥3. 7. pre-existing left ventricular ejection fraction <30%.